← Thiazolidinediones × all-cause mortality

SynthesisThe Cochrane database of systematic reviews2020

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Emil Ørskov Ipsen et al.PubMed ↗Full text ↗Publisher ↗

  • Pioglitazoneno clear effectNo clear effect on deaths, no clear effect on SAEs, no clear effect on cardiovascular deaths.Nothing cleared the noise.

What the trial testedas reported · 2,694 people · 2020

Range includes no effect

No clear effect on deaths

2.4×0.5× to 11×

pioglitazone vs placebo

Bigger than 9 in 10 for all-cause mortality

As reported

OR 2.38, 95% CI 0.54–10.5 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on SAEs

3×0.3× to 28×

pioglitazone vs placebo

3 in 100 instead of 1

Bigger than 9 in 10 for adverse events & safety

As reported

RR 3, 95% CI 0.32–28.2

Range includes no effect

No clear effect on cardiovascular deaths

5.1×0.3× to 106×

pioglitazone vs placebo

Bigger than almost all for cardiovascular events

As reported

RR 5.14, 95% CI 0.25–106 · the paper's word: cardiovascular mortality

Range includes no effect

No clear effect on deaths

−15%−62% to +91%

pioglitazone vs no intervention

2 in 100 instead of 3

Bigger than 5 in 10 for all-cause mortality

As reported

RR 0.85, 95% CI 0.38–1.91 · the paper's word: All-cause mortality

+1 more in the walkthrough ↓

Who was studied, and how

2,694people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

pioglitazone
placebo

No clear effect on deaths2.4×

No clear effect on SAEs3×

No clear effect on cardiovascular deaths5.1×

randomised

The trial randomly assignedassigned by chance

pioglitazone
no intervention

No clear effect on deaths−15%

No clear effect on SAEs−29%

randomised

the abstract, start to end

… in the placebo groups (Peto odds ratio 2.38, 95% CI 0.54 to 10.50; P = …

There were 3/93 participants with SAEs in …

… participants in the placebo group (RR 5.14, 95% CI 0.25 to 106.28; P = …

… in the no-intervention groups (RR 0.85, 95% CI 0.38 to 1.91; P = 0.70; …

… in the no-intervention groups (RR 0.71, 95% CI 0.38 to 1.32; P = 0.28; …

← favours treatmentfavours comparator →
could be chance
All-cause mortalitypioglitazone vs placebo
OR 2.380.54–10.5
SAEspioglitazone vs placebo
RR 30.32–28.2
Cardiovascular mortalitypioglitazone vs placebo
RR 5.140.25–106
All-cause mortalitypioglitazone vs no intervention
RR 0.850.38–1.91
SAEspioglitazone vs no intervention
RR 0.710.38–1.32
ThiazolidinedionesCardiovascular eventsAll-cause mortalityAdverse events & safety

Thiazolidinediones × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted

Thiazolidinediones × cardiovascular eventshelps?mixed

unlikelylikely
0.00not counted
← favours comparatorfavours treatment →
more certainless certain
1 / 7

9 papers cite it

2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 33210751